Medicare patients over 65 who want affordable weight loss drugs have a new option. Sort of.
The Trump administration launched a temporary “Bridge” demonstration project last July. It lets seniors and certain disabled people access popular glucagon-like peptide-1 (GLP-1) medications. Drugs like Zepbound, Foundayo, and Wegovy are now in reach.
For a flat $50 a month.
Sounds like a deal, right?
Not so fast. Questions linger. Eligibility criteria are strict. The prior authorization process is a hurdle. And the cost structure? It’s not as straightforward as a simple co-pay.
How the Medicare Bridge Program Works
This isn’t standard coverage. It’s a temporary demo running through December 2027. The goal is clear: bypass the 2006 law that prohibits Medicare from covering weight-loss drugs for obesity alone.
Here’s the breakdown of the Medicare Bridge program for weight loss medications :
- Eligible Drugs: Zepbound (tirzepatide) is covered only as the KwikPen (single-dose vials and other pens excluded). Foundayo (orforglipron is reimbursed at all dosage strengths. Wegovy (semaglutide) comes in both injectable and tablet forms.
- The Cost: A flat $50 monthly co-pay. No exceptions. This applies regardless of income.
- Government Cost: The federal government pays a net $245 per prescription monthly directly to manufacturers, minus the patient’s $50.
- Who Can Join: Beneficiaries over 65 or disabled individuals.
It’s simple on paper. Real life is messier.
Who Actually Qualifies? (And Who Gets Cut Out)
CMS has drawn hard lines. To qualify, you need specific body mass index (BMI) metrics and you must not have certain other conditions.
You must have:
– A BMI of 35 or higher.
– Or, a BMI between 27 and 35 plus an obesity-related comorbidity.
But there’s a catch. If you have type 2 diabetes, moderate-to-advanced sleep apnea, or MASH (metabolic dysfunction-associated steatohepatitis), you’re out.
Why? Because those conditions are already “covered” under standard outpatient benefits.
If your sleep apnea crosses the threshold from mild into moderate, you lose access to the Bridge program.
That’s what one physician told MedPage Today. You might have a BMI of 35. You might be desperate for Wegovy. But if your sleep apnea worsens to moderate, the program rejects you.
You get sent back to your standard Part D plan. Which might not cover it. Which might charge hundreds of dollars a month.
The disjointed rules leave patients in a gray zone. You’re managed by a different system now. The Bridge program operates completely outside standard Part D payment structures.
The Administrative Headache
Prescribers can’t just fax the prescription to the pharmacy. Or the plan.
They must submit requests to Bridge’s central processor, managed by CMS. No claims through standard PartD channels. Submit through standard channels and expect rejection.
Wait for it.
Processing these requests takes days. All of them. Every single prior authorization for Bridge prescriptions.
Patients with the Low-Income Subsidy (LIS) in Part D get no break. They’re used to paying little or nothing. Now they face that $50 flat fee.
Does $50 matter for a wealthy retiree? Maybe not. For seniors living on fixed incomes? It’s a significant expense. And those $50 payments don’t count toward deductibles or out-of-pocket maximums. It’s a sinkhole of cash with no relief valve.
Why BALANCE Failed (But Bridge Lives)
This program didn’t appear in a vacuum. It’s coupled with another pilot: BALANCE. Better Approaches to Lifestyle and Nutrition hEalth.
BALANCE was supposed to be voluntary. It aimed to expand GLP-1 access while tying it to manufacturer-supported lifestyle programs. CMS negotiated lower net prices. Theoretically, a win-win.
It failed.
Plan sponsors didn’t sign up. CMS needed an 80% participation threshold. They missed it. BALANCE is indefinitely paused.
Bridge moved forward without it.
Was cost the driver? CMS estimates the cost of adding obesity coverage to Part D between $25 billion and $30 billion over ten years. The Congressional Budget Office (CBO) warns that full enrollment of all 3.8 million eligible beneficiaries could exceed $30 billion annually.
Even if only 20% enroll? That’s roughly $6 billion a year.
$6 billion is a lot to crowd out other healthcare funding.
Curiously, CMS documentation excludes financial implications for either BALANCE or Bridge. No public cost estimates. Why?
Are they afraid to be wrong? Or deferring to the CBO? The silence is loud.
What Happens in 2028?
The Bridge demo ends in December 2027.
That’s two years away. But the clock is ticking.
If the Trump administration doesn’t extend Bridge, millions could stop their medications abruptly.
Think about that.
Sudden cessation of GLP-1s. Weight rebound. Return of comorbidities.
There are no guarantees of extension. Cost is a limiting factor. Spending on GLP1s for diabetes is already soaring. Adding obesity coverage—even at reduced prices—creates another massive liability.
For now, access is here. It’s messy. It’s bureaucratic. And it’s expensive for the taxpayer.
But for a senior who finally sees a path to affordable GLP-1s? The $50 fee feels like a miracle. Until the eligibility trap snaps shut. Until the admin delay bites. Until the program expires.
Which brings us back to the question no one is answering: Who really pays when this demo ends?
